Business Wire

GCORE

6.6.2024 10:31:30 CEST | Business Wire | Press release

Share
Gcore Unveils Inference at the Edge – Bringing AI Applications Closer to End Users for Seamless Real-Time Performance

Gcore, the global edge AI, cloud, network, and security solutions provider, today announced the launch of Gcore Inference at the Edge, a breakthrough solution that provides ultra-low latency experiences for AI applications. This innovative solution enables the distributed deployment of pre-trained machine learning (ML) models to edge inference nodes, ensuring seamless, real-time inference.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240606719181/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Gcore Inference at the Edge empowers businesses across diverse industries with cost-effective, scalable, and secure AI model deployment (Graphic: Gcore)

Gcore Inference at the Edge empowers businesses across diverse industries—including automotive, manufacturing, retail, and technology—with cost-effective, scalable, and secure AI model deployment. Use cases such as generative AI, object recognition, real-time behavioural analysis, virtual assistants, and production monitoring can now be rapidly realised on a global scale.

Gcore Inference at the Edge runs on Gcore's extensive global network of 180+ edge nodes, all interconnected by Gcore's sophisticated low-latency smart routing technology. Each high-performance node sits at the edge of the Gcore network, strategically placing servers close to end users. Inference at the Edge runs on NVIDIA L40S GPUs, the market-leading chip designed specifically for AI inference. When a user sends a request, an edge node determines the route to the nearest available inference region with the lowest latency, achieving a typical response time of under 30 ms.

The new solution supports a wide range of fundamental ML and custom models. Available open-source foundation models in the Gcore ML Model Hub include LLaMA Pro 8B, Mistral 7B, and Stable-Diffusion XL. Models can be selected and trained agnostically to suit any use case, before distributing them globally to Gcore Inference at the Edge nodes. This addresses a significant challenge faced by development teams where AI models are typically run on the same servers they were trained on, resulting in poor performance.

Benefits of Gcore Inference at the Edge include:

  • Cost-effective deployment: A flexible pricing structure ensures customers only pay for the resources they use.
  • Inbuilt DDoS protection: ML endpoints are automatically protected from DDoS attacks through Gcore’s infrastructure.
  • Outstanding data privacy and security: The solution features built-in compliance with GDPR, PCI DSS, and ISO/IEC 27001 standards.
  • Model autoscaling: Autoscaling is available to handle load spikes, so a model is always ready to support peak demand and unexpected surges.
  • Unlimited object storage: Scalable S3-compatible cloud storage that grows with evolving model needs.

Andre Reitenbach, CEO at Gcore comments: “Gcore Inference at the Edge empowers customers to focus on getting their machine learning models trained, rather than worrying about the costs, skills, and infrastructure required to deploy AI applications globally. At Gcore, we believe the edge is where the best performance and end-user experiences are achieved, and that is why we are continuously innovating to ensure every customer receives unparalleled scale and performance. Gcore Inference at the Edge delivers all the power with none of the headache, providing a modern, effective, and efficient AI inference experience.”

Learn more at https://gcore.com/inference-at-the-edge

About Gcore
Gcore is the global edge AI, cloud, network, and security solutions provider. Gcore provides its solutions to global leaders in numerous industries. The company manages its own global IT infrastructure across six continents, with one of the best network performances in Europe, Africa, and LATAM, due to the average response time of 30 ms worldwide. Gcore’s network consists of 180+ points of presence around the world in reliable Tier IV and Tier III data centres, with a total capacity exceeding 200 Tbps.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240606719181/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye